Background Clostridium difficile is a leading cause of morbidity and mortality in several
countries. However, there are limited evidence characterizing its role as a global public …

Clostridium difficile epidemiology has changed in recent years, with the emergence of highly
virulent types associated with severe infections, high rates of recurrences and mortality …

Abstract Scope In 2009, the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) published the first treatment guidance document for Clostridioides …

Triptolide (TP), a traditional Chinese medicine, has been reported to be effective in the
treatment of autoimmune diseases and exerting antineoplastic activity in several human …

OBJECTIVEAn estimated 20–30% of patients with primary Clostridium difficile infection
(CDI) develop recurrent CDI (rCDI) within 2 weeks of completion of therapy. While the actual …

Importance Gastric acid suppression has been associated with an increased risk of
primaryClostridium difficile infection (CDI), but the risk of recurrent CDI in patients taking …

Once thought to be an inconvenient complication of antimicrobials, Clostridium difficile is
now the most common pathogen to cause health care–associated infections (HAIs) in the …

The incidence of Clostridium difficile infection (CDI) continues to rise, whilst treatment
remains problematic due to recurrent, refractory and potentially severe nature of disease …

Background Proton pump inhibitor (PPI) therapy is a potentially modifiable risk factor for
recurrent Clostridioides difficile infection (CDI). Citing an absence of clinical trials, many …

Clostridium difficile (C. difficile) is the most prevalent causative pathogen of healthcare‐
associated diarrhea. Notably, over the past 10 years, the number of Clostridium difficile …